Study title Intervention Study size Description Status Country Reference Treatment of COVID-19 patients using Wharton’s Jelly-Mesenchymal Stem Cells WJ-MSCs 5 Dose: 3 IV doses of 1×10e6/kg Phase 1 Jordan 55 Time: 3 days apart Safety and Efficacy study of Allogenic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients Allogenic Human Dental Pulp MSCs 20 Dose: IV of 3.0x10e7 human dental pulp stem cell solution (30 ml) on day 1, day 4 and day 7 Phase 2 China 56 Placebo: Intravenous Saline IV of 3 ml of 0.9% saline at the same interval NestCell Mesenchymal Stem Cells to Treat Patients with Severe COVID-19 Pneumonia NestCell 66 Dose: 2×107 cells (20 million cells) Phase 1 Brazil 57 Time: days 1, 3 and 5 in addition to standard care. On day 7, cells will only be administered if necessary A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19 HB-adMSCs 100 3 groups of patients, will receive five IVs at 200, 100 and 50 million cells/dose Phase 2 USA 58 Infusions will occur at week 0, 2, 6, 10 and 14. Placebo is saline Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19 Allogenic expanded adMSCs 26 Two doses of 80 million adipose-tissue derived mesenchymal stem cells Phase 2 Spain 59 A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19 HB-adMSCs 56 Dose: five IV infusions Phase 2 USA 60 Time: follow-up inflammatory data will be obtained at 6, 14, 26 weeks; and PHQ-9 Questionnaires at weeks 2, 6, 10, 14, 18, 22, 26 Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem cells Dental pulp MSCs 24 Dose: 1.0×106 cells/kg Early Phase 1 China 51 The injection of dental mesenchymal stem cells will be increased on day 1, 3 and 7 Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19 MSCs 20 China 61 Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19) MSCs 90 3 times of MSCs (3.0*10E7 MSCs intravenously at Day 0, Day 3, Day 6) Phase 1 China 62 Saline containing 1% Human serum albumin (solution of MSC) Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19) BM-MSCs 20 Participants will receive conventional treatment plus BM-MSCs (1*10E6/kg body weight intravenously at Day 1) Phase 2 China 63 Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19 UC-MSCs 48 4 times of UC-MSCs (0.5*10E6 UC-MSCs/kg body weight intravenously at Day 1, Day 3, Day 5, Day 7) Not yet recrui-ting China 64 Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019 Drug: Oseltamivir and hormones MSCs 60 Umbilical cord mesenchymal stem cells were given at 106/Kg body weight/time, once every 4 days for a total of 4 times Peripheral intravenous infusion was given within 3 days of first admission Early Phase 1 China 53 Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia UC-MSCs 30 1*10E6 UC-MSCs/kg suspended in 100 ml saline Phase 2 China 65 Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome Cell therapy 60 Protocol 1 (n=20). Two doses of MSCs 100×10e6 (± 10%) at Day 0 and Day 2 plus Conventional treatment Phase 3 Iran 66 Protocol 2: Two doses of MSCs 100×10e6 (± 10%)at Day 0 and Day 2, intravenously plus two doses of EVs at Day 4 and Day 6 plus conventional treatment Role of Immune and Inflammatory Response in Recipients of Allogeneic Haematopoietic Stem Cell Transplantation (SCT) Affected by Severe COVID19 No intervention 40 Comparison of biomarkers Active, not re-cruiting United King-dom 67 Use of UC-MSCs for COVID-19 Patients UC-MSCs 24 UC-MSC will be administered at 100×106 cells/infusion administered intravenously in addition to the standard of care treatment Phase 2 USA 68 Stem Cell Educator Therapy Treat the Viral Inflammation in COVID-19 Stem Cell Educator-Treated Mononuclear Cells Apheresis 20 SCE therapy circulates a patient’s blood through a blood cell separator, briefly cocultures the patient’s immune cells with adherent CB-SC in vitro, and returns the autologous immune cells to the patient’s circulation Phase 2 USA 69 Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19 Drug: HB-and MSC 110 Dose: 4 IV of HB-adMSCs at 100 million cells/dose + hydroxychloroquine and azithromycin Phase 2 USA 54 Drug: Placebo HB-adMSC infusions will occur at day 0, 3, 7, and 10 Drug: HC Placebo: similar intervals without the HB-adMSCs Drug: AZ Therapy for Pneumonia Patients Infected by 2019 Novel Coronavirus Biological: UC-MSCs N.A 0.5*10E6 UC-MSCs/kg body weight suspended in 100 ml saline containing 1% human albumin intravenously at Day 1, Day 3, Day 5, Day 7 With-drawn China 70 Battle Against COVID-19 Using Mesenchymal Stromal Cells Allogeneic and expanded adipose tissue-derived MSCs 100 Two serial doses of 1.5 million adipose-tissue derived mesenchymal stem cells/kg Phase 2 Madrid 71 Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS CAStem 9 A dose-escalation with 3 cohorts with 3 patients/cohort who receive doses of 3, 5 or 10 million cells/kg Phase 2 China 72 ASC Therapy for Patients With Severe Respiratory COVID-19 Stem Cell Product 40 100 million allogeneic adipose-derived mesenchymal stromal cells diluted in 100 ml saline Phase 2 Denmark 73 Mesenchymal Stem Cells (MSCs) in Inflammation-Resolution Programs of Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS) MSC 40 Infusion of allogeneic bone marrow-derived human mesenchymal stem (stromal) cells Phase 2 Germany 74 Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus (nCOV) Pneumonia UC-MSCs 10 UC-MSCs infusion intravenously on day 1, day 3, day 5, and day 7 Phase 2 China 75 A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia MSCs-derived exosomes 30 5 times aerosol inhalation of MSCs-derived exosomes (2.0*10E8 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5) Phase 1 China 50 MultiStem Administration for COVID-19 Induced ARDS (MACoVIA) MultiStem 400 IV infusion of MultiStem Phase 3 USA 76 Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS UC Wharton’s jelly-derived human 60 Dose: 1 million/kg through an intravenous route Phase 2 France 48 Placebo: NaCl 0.9% Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV) Mesenchymal Stromal Cells 24 IV injection of 1 million MSV cells/Kg diluted in 100 ml saline Phase 2 Spain 77 Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease) Mesenchymal Stromal Cells 30 Dose:1 × 108 MSCs through IV Early Phase 1 USA 78 Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST) (COVID-19) Remestemcel-L 300 Administered twice during the first week, with the second infusion at 4 days following the first injection (± 1 day) Phase 3 USA 79 Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells Allogenic pooled olfactory mucosa-derived MSCs 40 IV injection Phase 2 Minsk 52 Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19 Autologous adMSCs 200 3 doses of 200 million cells through IV every 3 days Phase 2 USA 49 Mesenchymal Stem Cell Infusion for COVID-19 Infection MSCs 20 Dose: 2 × 106 cells/kg, administered on day 1, 7 in addition to supportive care Phase 2 Pakistan 80 Safety and Efficacy of Mesenchymal Stem Cells in the Management of Severe COVID-19 Pneumonia (CELMA) UC-MSCs 30 Dose: 1*106 cells/Kg Phase 2 USA 81 Mesenchymal Stem Cell for Acute Respiratory Distress Syndrome Due for COVID-19 (COVID-19) MSC 10 Dose: 1 million/Kg Phase 2 Mexico 82 NestaCellⓇ Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia (HOPE) NestaCellⓇ 90 Dose : 2×107 cells on days 1, 3, 5 and 7 Phase 2 Brazil 83 Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19) UC-MSCs 100 Dose: 3 of 4.0*10E7 cells at Day 0, Day 3, Day 6 Phase 2 China 84 Efficacy of Intravenous Infusions of Stem Cells in the Treatment of COVID-19 Patients MSCs 20 IV injection of Cultured stem cells at days 1, 3 and 5 Phase 2 Turkey 85 Clinical Use of Stem Cells for the Treatment of Covid-19 MSCs 30 Dose: 3 million cells/kg on days 0, 3 and 6 Phase 2 Turkey 86 Safety and Efficacy of Intravenous Wharton’s Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19 WJ-MSCs 40 2 doses Phase 2 Colombia 87 MSCs in COVID-19 ARDS Remestemcel-L 300 Twice in the first week with a gap of 4 days between the injections Phase 3 USA 88 Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19 (COVIDMES) WJ-MSCs 30 Administration along with standard care Phase 2 Spain 89 Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome - Vanguard (CIRCA-19) MSCs 9 IV administration Phase 1 Canada 90 ACT-20 in Patients With Severe COVID-19 Pneumonia Allogenic UC-MSCs 70 1 million cells/kg body weight in 100 ml in conditioned media Phase 2 91 Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation Allogenic BM-MSC 45 IV administration Phase 1 USA 92 Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19 MSCs 140 15 IM injections (1 ml each). Twice with an interval of 1 week Phase 2 USA 93 A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy MSCs and a plasmapheresis device 24 Administered through integration into a Continuous Renal Replacement Therapy circuit Phase 2 94